Friday March 12th 2021
Up to 96.4 percent
Novavax shows high effectiveness in studies
Hopeful news from the US vaccine manufacturer Novavax – with a small damper: Studies have shown the active ingredient to be highly effective against the conventional virus and B.1.1.7. However, the effectiveness against the variant widespread in South Africa is rather weaker.
The corona vaccine from the US company Novavax has shown high effectiveness against severe courses of Covid-19 in studies. On the other hand, the effectiveness against mild and moderate courses, especially the South African variant, is significantly less good, the company said.
As part of a phase 3 study in the UK, the active ingredient was tested on 15,000 people between 18 and 84 years of age, the company announced. The effectiveness against light, moderate and severe courses of the conventional variant of the virus is therefore 96.4 percent. The effectiveness against mutant B.1.1.7 is 89.7 percent.
In South Africa, the company tested the vaccine in a phase 2 study in around 2,600 people. The effectiveness was only 48.6 percent, in HIV-negative people it was 55.4 percent. In both studies, however, the vaccine showed one hundred percent protection against severe courses.
The Maryland-based company said it intends to apply for approval for the vaccine first in the UK and then in the US in early April. The European Medicines Agency (EMA) has already started a review process for the vaccine.
Only yesterday was the fourth active ingredient approved in the European Union with the vaccine from the US company Johnson & Johnson. The two mRNA vaccines from Biontech / Pfizer and Moderna as well as the vector vaccine from the British-Swedish manufacturer Astrazeneca are already in use.